Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06242691 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT06242691 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 13 participants.
The verdict
NCT06242691, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses
Interventions
- BIOLOGICAL MK-1200
- DRUG Antiemetic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06242691
The ClinicalTrials.gov registry entry for NCT06242691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-1200 is the first listed.
NCT06242691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06242691 about?
NCT06242691 is a clinical study titled "Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)". The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all t...
What is the current status of trial NCT06242691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-02-28. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT06242691?
The interventions under investigation include: MK-1200 (BIOLOGICAL), Antiemetic (DRUG).
Who is sponsoring clinical trial NCT06242691?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.